Corxel has raised $287 million to fund its projects as obesity continues to spark investor interest. The company's main candidate, the drug CX11, is currently being tested in clinical trials. A phase II trial is underway in the USA. In China, the drug CX11 is in phase III trials. This information comes from an article on investment interest in obesity.